Ropes & Gray recently advised Akebia Therapeutics Inc. on its initial public offering of 6.7 million shares of its common stock at a price of $17 per share. Akebia is a Cambridge, Mass.-based biopharmaceutical company developing novel therapeutics aimed at patients with kidney disease. The IPO was announced Feb. 18 and closed March 25, with the net proceeds of the offering totaling $106.9 million.
Christopher Comeau led the Ropes & Gray team representing Akebia.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.